1888
C.L. Wainwright et al
NCX4016 reduces myocardial ischaemia/reperfusion injury
BARNES, C.S. & COKER, S.J. (1995). Failure of nitric oxide donors to
alter arrhythmias induced by acute myocardial ischaemia or
reperfusion in anaesthetized rats. Br. J. Pharmacol., 114, 349 ±
356.
BONOW, R.O., LIPSON, L.C., SHEEHAN, F.H., CAPURRO, N.L.,
ISNER, J.M., ROBERTS, W.C., GOLDSTEIN, R.E. & EPSTEIN, S.E.
(1981). Lack of eect of aspirin on myocardial infarct size in the
dog. Amer. J. Cardiol., 47, 258 ± 264.
COKER, S.J., LEDINGHAM, I.McA., PARRATT, J.R. & ZEITLIN, I.J.
(1981a). Aspirin inhibits the early myocardial release of
thromboxane B2 and ventricular ectopic activity following acute
coronary occlusion in dogs. Br. J. Pharmacol., 72, 593 ± 595.
COKER, S.J. & PARRATT, J.R. (1983). Prostacyclin ± antiarrhythmic
or arrhythmogenic? Comparison of the eects of intravenous and
intracoronary prostacyclin and ZK 36374 during coronary artery
occlusion and reperfusion in anaesthetised greyhounds. J.
Cardiovasc. Pharmacol., 5, 557 ± 567.
COKER, S.J., PARRATT, J.R., LEDINGHAM, I. McA. & ZEITLIN, I.J.
(1981b). Thromboxane and prostacyclin release from the
ischaemic myocardium in relation to arrhythmias. Nature, 291,
323 ± 324.
COL, N.F., YARZEBSKI, J., GORE, J.M., ALPERT, J.S. & GOLDBERG,
R.J. (1995). Does aspirin consumption aect the presentation or
severity of acute myocardial infarction? Arch. Int. Med., 155,
1386 ± 1389.
DE CATERINA, R., LIBBY, P., PENG, H.B., THANNICKAL, V.J.,
RAJAVASHTISH, T.B., GIMBRONE, M., SHIN, W.S. & LIAO, J.K.
(1995). Nitric oxide decreases cytokine-induced endothelial
activation: nitric oxide selectively reduces endothelial expression
of adhesion molecules and proin¯ammatory cytokines. J. Clin.
Invest., 96, 60 ± 68.
MULLANE, K.M. & FORNABAIO, D. (1988). Thromboxane synthe-
tase inhibitors reduce infarct size by a platelet-dependent aspirin-
sensitive mechanism. Circ. Res., 62, 668 ± 678.
NOSSULI, T.O., HAYWARD, R., SCALIA, R. & LEFER, A.M. (1997).
Peroxynitrite reduces myocardial infarct size and preserves
coronary endothelium after ischemia and reperfusion in cats.
Circulation, 96, 2317 ± 2324.
PABLA, R. & CURTIS, M.J. (1995). Eects of NO modulation on
cardiac arrhythmias in the rat isolated heart. Circ. Res., 77, 984 ±
992.
PARRATT, J.R., COKER, S.J.
& WAINWRIGHT, C.L. (1987).
Eicosanoids and susceptibility to ventricular arrhythmias during
myocardial ischaemia and reperfusion. J. Mol. Cell. Cardiol., 19
(Suppl V), 55 ± 66.
ROSSONI, G., MANFREDI, B., COLONNA, V.D.G., BERNAREGGI, M.
& BERTI, F. (2001). The nitroderivative of aspirin, NCX4016,
reduces infarct size caused by myocardial ischaemia in the
anaesthetised rat. J. Pharmacol. Exp. Ther., 297, 380 ± 387.
SMITH, W.T., FLEET, W.F., JOHNSON, T.A., ENGLE, C.L. & CASCIO,
W.E. (1995). The 1b phase of ventricular arrhythmias in ischaemic
in situ porcine heart is related to changes in cell-to-cell electrical
coupling. Circulation, 92, 3051 ± 3060.
SPIECKER, M., PENG, H.B.
& LAIO, J.K. (1997). Inhibition of
endothelial vascular cell adhesion molecule expression by nitric
oxide involves induction and nuclear translocation of IkBa. J.
Biol. Chem., 271, 11317 ± 11324.
SUCH, L., MORCILLO, E., VINA, J.
& ESPLUGUES, J. (1981).
Dierential eects of anti-in¯ammatory agents on canine acute
myocardial infarction. IRCS Med. Sci., 9, 574 ± 575.
SUN, W. & WAINWRIGHT, C.L. (1997). The role of nitric oxide in
modulating ischaemia-induced arrhythmias in rats. J. Cardio-
vasc. Pharmacol., 29, 554 ± 562.
VERHEUGT, F.W.A., VAN DER LAARSE, A., FUNKE-KUPPER, A.J.,
STERKMAN, L.G.W., GALEMA, T.W. & ROOS, J.P. (1990). Eects
of early intervention with low-dose aspirin (100 mg) on infarct
size, reinfarction and mortality in anterior wall acute myocardial
infarction. Amer. J. Cardiol., 66, 267 ± 270.
WAINWRIGHT, C.L. & MARTORANA, P. (1993). Pirsidomine, a novel
nitric oxide donor, suppresses ischemic arrhythmias in anaes-
thetized pigs. J. Cardiovasc. Pharmacol., 22 (Suppl 7), S44 ± S50.
DEMIRYUREK, A.T., WAINWRIGHT, C.L., WADSWORTH, R.M. &
KANE, K.A. (1994). Characterization of
a
method for the
detection of drugs with free radical scavenging activity using
porcine activated leukocytes. J. Pharmacol. Meth., 32, 35 ± 40.
FLORES, N.A., GOULIELMOS, N.V., SEGHATCHIAN, M.J. & SHER-
IDAN, D.J. (1994). Myocardial ischaemia induces platelet
activation with adverse electrophysiological and arrhythmogenic
eects. Cardiovasc. Res., 28, 1662 ± 1671.
GOLINO, P., AMBROSIO, G., VILLARI, B., RAGNI, M., FOCACCIO, A.,
PACE, L., DE CLERK, F., CONDORELLI, M. & CHIARIELLO, M.
(1993). Endogenous prostacyclin endoperoxides may alter infarct
size in the presence of thromboxane synthetase inhibition:
WAINWRIGHT, C.L.
& PARRATT, J.R. (1988). The eects of
L655,240, a selective thromboxane and prostaglandin endoper-
oxide antagonist, on ischemia- and reperfusion-induced cardiac
arrhythmias. J. Cardiovasc. Pharmacol., 12, 264 ± 271.
Studies in a rabbit model of coronary artery occlusion-
reperfusion. J. Amer. Coll. Cardiol., 21, 493 ± 501.
WAINWRIGHT, C.L. & PARRATT, J.R. (1991). Failure of cyclo-
HOHLFELD, T., STROBACH, H. & SCHROR, K. (1993). Stimulation of
endogenous prostacyclin protects the reperfused pig myocardium
from ischemic injury. J. Pharmacol. Exp. Ther., 264, 397 ± 405.
KENNEDY, S., WADSWORTH, R.M., MCPHADEN, A.R. & WAIN-
oxygenase inhibition to protect against arrhythmias induced by
ischaemia and reperfusion: implications for the role of
prostaglandins as endogenous myocardial protective substances.
Cardiovasc. Res., 25, 93 ± 100.
WRIGHT, C.L. (2000).
measuring leukocyte adhesion to normal and balloon-injured
arteries in vitro. J. Imm. Meth., 244, 153 ± 162.
A
rapid, quantitative method for
WALKER, M.J.A., CURTIS, M.J., HEARSE, D.J., CAMPBELL, R.W.F.,
JANSE, M.J., YELLON, D.M., COBBE, S.M., COKER, S.J., HAR-
NESS, J.B., HARRON, D.W.G., HIGGINS, A.J., JULIAN, D.G., LAB,
M.J., MANNING, A.S., NORTHOVER, B.J., PARRATT, J.R.,
RIEMERSMA, R.A., RIVA, E., RUSSELL, D.C. SHERIDAN, D.J.,
WINSLOW, E. & WOODWARD, B. (1988). The Lambeth Conven-
tions: guidelines for the study of arrhythmias in ischaemia,
reperfusion and infarction. Cardiovasc. Res., 22, 447 ± 455.
WALLACE, J.L., MCKNIGHT, W., DEL SOLDATO, P., BAYDOUN, A.R.
& BIRINO, G. (1995). Anti-thrombotic eects of a nitric oxide-
releasing, gastric-sparing aspirin derivative. J. Clin. Invest., 96,
2711 ± 2718.
KIMURA, A., ROSETO, J., SUH, K.-Y., COHEN, A.M. & BING, R.J.
(1998). Eect of acetylsalicylic acid on nitric oxide production in
infarcted heart in situ. Biochem. Biophys. Res. Comm., 251, 874 ±
878.
LEFER A.M., SIEGFRIED, M.R. & MA, X.-L. (1993a). Protection of
ischemia-reperfusion injury by sydnonimine donors via inhibi-
tion of neutrophil-endothelium interaction. J. Cardiovasc.
Pharmacol., 22 (Suppl 7), S27 ± S33.
LEFER, D.J., NAKANISHI, K.
Endothelial and myocardial cell protection by
&
VINTEN-JOHANSEN, J. (1993b).
cysteine-
a
YAMAMOTO, T., COHEN, A.M., KAKAR, N.R., YAMAMOTO, M.,
JOHNSON, P.E. CHO, Y.K. & BING, R.J. (1999). Production of
prostanoids and nitric oxide by infarcted heart in situ and the
eect of aspirin. Biochem. Biophys. Res. Comm., 257, 488 ± 493.
containing nitric oxide donor after myocardial ischaemia and
reperfusion. J. Cardiovasc. Pharmacol., 22, (Suppl 7), S34 ± S43.
MINUZ, P., LECHI, C., ZULIANI, V., GAINO, S., TOMMASOLI, R. &
LECHI, A. (1998). NO-aspirins: Antithrombotic activity of
derivatives of acetyl salicylic acid releasing nitric oxide.
Cardiovasc. Drug Rev., 16, 31 ± 47.
(Received December 18, 2001
Accepted January 31, 2002)
MORRIS, J.L. & COWAN, J.C. (1995). Nitrates in myocardial
infarction: a current perspective. Can. J. Cardiol., 11 (Suppl B),
5B ± 10B.
British Journal of Pharmacology vol 135 (8)